These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29921501)

  • 21. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
    Hartrick CT
    Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?
    Caraci F; Coluzzi F; Marinangeli F; Mercadante S; Rinonapoli G; Romualdi P; Nicora M; Dickenson AH
    Curr Med Res Opin; 2020 Jun; 36(6):1015-1024. PubMed ID: 32216591
    [No Abstract]   [Full Text] [Related]  

  • 23. Tapentadol (Nucynta)--a new analgesic.
    Med Lett Drugs Ther; 2009 Aug; 51(1318):61-2. PubMed ID: 19661853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
    Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
    Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo characterization of tapentadol metabolites.
    Terlinden R; Kogel BY; Englberger W; Tzschentke TM
    Methods Find Exp Clin Pharmacol; 2010; 32(1):31-8. PubMed ID: 20383344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.
    Bee LA; Bannister K; Rahman W; Dickenson AH
    Pain; 2011 Jan; 152(1):131-139. PubMed ID: 21187272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.
    Schröder W; Tzschentke TM; Terlinden R; De Vry J; Jahnel U; Christoph T; Tallarida RJ
    J Pharmacol Exp Ther; 2011 Apr; 337(1):312-20. PubMed ID: 21262850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence.
    Ahsan MZ; Zhao MJ; Shoaib RM; Zhang Y; Wang YX
    Life Sci; 2021 Nov; 285():119996. PubMed ID: 34597607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is tapentadol an advance on tramadol?
    Guay DR
    Consult Pharm; 2009 Nov; 24(11):833-40. PubMed ID: 20092221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy.
    Gonçalves L; Friend LV; Dickenson AH
    Eur J Pharmacol; 2015 Feb; 749():151-60. PubMed ID: 25576174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tapentadol Prolonged Release: A Review in Pain Management.
    Deeks ED
    Drugs; 2018 Nov; 78(17):1805-1816. PubMed ID: 30471002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis.
    Tzschentke TM; Folgering JH; Flik G; De Vry J
    Neurosci Lett; 2012 Jan; 507(2):151-5. PubMed ID: 22197547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action.
    Caputi FF; Nicora M; Simeone R; Candeletti S; Romualdi P
    Minerva Med; 2019 Feb; 110(1):62-78. PubMed ID: 30667206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.
    Baron R; Eberhart L; Kern KU; Regner S; Rolke R; Simanski C; Tölle T
    Pain Pract; 2017 Jun; 17(5):678-700. PubMed ID: 27611642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain.
    Mao XF; Ahsan MZ; Apryani E; Tang XQ; Zhao MJ; Li XY; Wang YX
    Eur J Pharmacol; 2020 Jun; 876():173062. PubMed ID: 32173379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tapentadol and nitric oxide synthase systems.
    Bujalska-Zadrożny M; Wolińska R; Gąsińska E; Nagraba Ł
    Behav Pharmacol; 2015 Apr; 26(3):282-8. PubMed ID: 25485639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.